商务合作
动脉网APP
可切换为仅中文
Calytrix Bio
Calytrix Bio
Calytrix Bio's potentially best-in-class preclinical program is a novel biparatopic antibody designed to deliver pan-mutant calreticulin activity
Calytrix Bio 潜在的同类最优临床前项目是一种新型双表位抗体,旨在提供针对所有突变型钙网蛋白的活性
Acquisition broadens Lilly's presence in the myeloproliferative neoplasm field and builds on Lilly's established capabilities in blood cancers
此次收购扩大了礼来在骨髓增殖性肿瘤领域的影响力,并进一步巩固了礼来在血液癌症方面的既有优势。
WELLESLEY, Mass.
马萨诸州韦尔斯利
,
,
Nov. 16, 2026
2026年11月16日
/PRNewswire/ -- Calytrix Bio, Inc. ('Calytrix'), a company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms (MPNs), today announced a definitive agreement for Eli Lilly and Company ('Lilly') to acquire Calytrix.
/美通社/ -- 致力于为骨髓增殖性肿瘤(MPN)患者开发精准疾病修饰疗法的Calytrix Bio, Inc.(“Calytrix”)今日宣布,已与礼来公司(“Lilly”)就后者收购Calytrix达成最终协议。
Calytrix's lead asset is an investigational biparatopic antibody for mutant calreticulin (mCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF). It is designed to deliver disease-modifying pan-mutant activity, with a safety and convenience profile that supports early intervention and long-term treatment.
Calytrix 的核心资产是一款在研的双表位抗体,用于治疗由突变型钙网蛋白(mCALR)驱动的原发性血小板增多症(ET)和骨髓纤维化(MF)。该抗体旨在提供具有疾病修饰作用的全突变体活性,其安全性和便利性支持早期干预和长期治疗。
Current drug therapies for ET and MF primarily manage symptoms and complications, creating an opportunity for precision therapies that target the disease driver mutations. Mutant CALR provides a tumor-specific cell-surface target with the potential to deplete the disease-driving mutant clone while sparing normal tissues and preserving healthy hematopoiesis..
目前针对原发性血小板增多症(ET)和骨髓纤维化(MF)的药物治疗主要侧重于管理症状和并发症,这为开发靶向疾病驱动突变的精准疗法提供了契机。突变型CALR提供了一种肿瘤特异性的细胞表面靶点,有望在清除驱动疾病的突变克隆的同时, sparing正常组织并保留健康的造血功能。
'Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms,' said Brad Prosek, President and Chief Executive Officer of Calytrix Bio. 'From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision.
Calytrix Bio 总裁兼首席执行官 Brad Prosek 表示:“Calytrix 的创立基于这样一种信念:骨髓增殖性肿瘤(MPN)患者值得拥有不止于控制症状的治疗方案。从一开始,我们的目标就是改变由 mCALR 驱动的原发性血小板增多症(ET)和骨髓纤维化(MF)的疾病进程。此次交易代表着我们在加速实现这一愿景方面迈出了重要一步。”
We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix's program to the starting line for clinical development.'.
我们期待礼来公司推动该项目进入临床试验阶段,并探索其在整个疾病谱系中惠及患者的潜力。我深深感谢我们的团队、科学顾问以及坚定的投资者,正是他们的支持,使Calytrix的项目顺利抵达临床开发的起跑线。
Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.
根据协议条款,礼来公司将收购Calytrix,Calytrix的股东最多可获得15亿美元的现金,包括预付款以及在达成某些临床和监管里程碑后的后续付款。
Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm within J.P. Morgan Asset Management. The company launched with a Series A financing co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners, followed by a Series B financing led by Avoro Ventures..
Calytrix 由摩根大通资产管理旗下的生命科学风险投资部门——摩根大通生命科学私募资本于 2025 年创立。公司启动时完成了由摩根大通生命科学私募资本和 Westlake BioPartners 联合领投的 A 轮融资,随后又完成了由 Avoro Ventures 领投的 B 轮融资。
For Calytrix, Centerview Partners LLC is acting as exclusive financial advisor, and Goodwin Procter LLP is acting as legal counsel. For Lilly, Paul, Weiss, Rifkind, Wharton & Garrison LLP is acting as legal counsel.
就Calytrix而言,Centerview Partners LLC担任其独家财务顾问,Goodwin Procter LLP担任其法律顾问。就Lilly而言,Paul, Weiss, Rifkind, Wharton & Garrison LLP担任其法律顾问。
About Calytrix Bio
关于 Calytrix Bio
Calytrix Bio is a privately held biotechnology company developing precision, disease-modifying therapies for patients living with myeloproliferative neoplasms. The company's initial focus is mCALR-driven essential thrombocythemia and myelofibrosis. Calytrix Bio's lead preclinical program is a novel biparatopic antibody designed to deliver pan-mutant activity by targeting both Type 1 and Type 2 mCALR, with the goal of providing disease-modifying therapy with safety and convenience that support early intervention and long-term treatment.
Calytrix Bio 是一家私人持有的生物技术公司,致力于为骨髓增殖性肿瘤患者开发精准的疾病修饰疗法。公司的初步重点是 mCALR 驱动的原发性血小板增多症和骨髓纤维化。Calytrix Bio 的主要临床前项目是一种新型双表位抗体,旨在通过同时靶向 1 型和 2 型 mCALR 突变体,提供泛突变活性,目标是提供一种具有安全性和便利性的疾病修饰疗法,以支持早期干预和长期治疗。
Calytrix Bio is based in Wellesley Hills, Massachusetts..
Calytrix Bio 总部位于马萨诸塞州韦尔斯利山。
SOURCE Calytrix Bio
来源:Calytrix Bio